Gene Therapies For Ocular Disease With Sparing Vision's Stéphane Boissel

We love to hear from our listeners. Send us a message. Since assuming the President and CEO role at Sparingvision in August, 2020, Stéphane Boissel has been  making big moves in the arenas of talent acquisition and IP expansion.  Those efforts are securing the company's development of  a number of genomic medicines to address inherited retinal disease. On this episode of the Business of Biotech, Boissel shares the company's foundation story and the role venture philanthropy played in it, his strategy for attracting and retaining big-league talent, and the why behind  his vigorous allegiance to internal development. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: [email protected] Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/